Trials / Unknown
UnknownNCT04768270
The Culture of Ovarian Cancer Organoids and Drug Screening
Drug Screening of Patient-derived Organoids From Ovarian Cancer Culture to Personalized Therapy,an Exploratory Research
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Chongqing University Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancer(OC) patients.
Detailed description
Tissue will be received from operative specimens( primary ovarian carcinoma) at time of primary cytoreductive surgery.Ovarian cancer(OC) organoids will be then cultured. Organoids will be validated with a combination of Next Generation Sequencing (NGS) analysis and immunohistochemistry (TP53, PAX8 etc). After then, the patient-derived organoids cultured from OC will be compared the sensitivity to standard regimens (chemotherapies and targeted agents) recommendated by NCCN guidlines versus patients treated in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | It is an observation trial. |
Timeline
- Start date
- 2022-04-12
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2021-02-24
- Last updated
- 2023-08-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04768270. Inclusion in this directory is not an endorsement.